Chronic rhinosinusitis (CRS) is a common extrapulmonary manifestation of cystic fibrosis (CF), significantly affecting pediatric patients' quality of life. TAS2R38 polymorphisms have been implicated in sinonasal innate immunity and may influence CRS severity and treatment response. Data on the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on sinonasal disease in children remain limited. This study evaluates the effects of ETI on CRS severity and explores the influence of atopy and TAS2R38 polymorphisms. We performed a single-center retrospective cohort study including CF subjects aged 6-18 years treated with ETI. Clinical, endoscopic, radiological, functional, and laboratory data were collected at baseline and after 12 months. CRS severity was assessed using Lund-Kennedy score, Lund-Mackay CT score, and Visual Analogue Scale (VAS). Secondary outcomes included quality of life (CFQ-R), lung function (FEV1), airway microbiology, atopy, and TAS2R38 genotype. Appropriate parametric and non-parametric tests were used (p < 0.05). Fifty-four patients (mean age 11.5 ± 3.6 years) were included. After 12 months of ETI, significant improvements were observed in FEV1, CFQ-R, VAS, endoscopic and radiological CRS scores. No patient required sinonasal surgery during follow-up. Staphylococcus aureus colonization was significantly reduced. Atopic patients showed lower radiological improvement than non-atopic subjects. TAS2R38 genotype was associated with baseline radiological severity, with higher Lund-Mackay scores in AVI/AVI patients. A genotype-dependent trend in ETI response was observed, with PAV/PAV patients showing less radiological improvement. ETI significantly improves CRS severity in pediatric CF patients. Atopy and genetic modifiers may contribute to variability in sinonasal response, supporting personalized management of CF-related CRS.
Background: Rett syndrome (RS) is a rare neurodevelopmental disorder primarily affecting females, characterized by severe neurological impairment and complex comorbidities, including epilepsy, scoliosis, and respiratory dysfunction. Respiratory complications, such as recurrent infections and sleep-disordered breathing (SDB), are increasingly recognized as significant contributors to morbidity. This study aimed to evaluate the prevalence, severity, and management of major comorbidities—including epilepsy, scoliosis, respiratory infections, and SDB—in a pediatric cohort with genetically confirmed RS. Methods: We conducted a retrospective review of medical records from 23 female patients under 18 years of age with MECP2 mutations, referred to our tertiary care center from 2021 to 2025. Data on epilepsy, scoliosis, respiratory infections, and nutritional status were collected. The presence of SDB was assessed through overnight home polygraphy (oPG) and transcutaneous carbon dioxide monitoring in selected cases. Results: Epilepsy affected 65% of patients, all with good seizure control. Scoliosis was present in 52%, with two patients requiring spinal surgery. At least one episode of lower respiratory tract infection (LRTI) was presented in 39% of our girls. LRTIs positively correlated with the number of hospitalization and antibiotic treatment. Among patients undergoing oPG, 67% presented obstructive sleep apnea, with its severity positively correlating with the frequency of lower respiratory infections. Severe nocturnal hypercapnia was documented in three patients, leading to non-invasive or invasive ventilation. Conclusions: Our findings highlight the high prevalence of sleep-related respiratory disorders and their association with respiratory infections in children with RS. Systematic respiratory assessment, including sleep studies, and early implementation of airway clearance techniques and ventilatory support are crucial to improving clinical outcomes in this vulnerable population.
BackgroundChronic rhinosinusitis (CRS) is a common extrapulmonary manifestation of cystic fibrosis (CF) and significantly affects pediatric patients’ quality of life. Data on the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on sinonasal disease in children remain limited. This study aims to evaluate the effects of ETI on CRS severity and explore the influence of atopy and TAS2R38 polymorphisms.MethodsWe performed a single-center retrospective cohort study including CF subjects aged 6–18 years treated with ETI. Clinical, endoscopic, radiological, functional, and laboratory data were collected at baseline and after 12 months of therapy. CRS severity was assessed using Lund–Kennedy endoscopic score, Lund–Mackay CT score and Visual Analogue Scale (VAS). Secondary outcomes included quality of life (CFQ-R), lung function (FEV1), airway microbiology, atopy, and TAS2R38 genotype. Appropriate parametric and non-parametric tests were used (p < 0.05).ResultsFifty-four patients (mean age 11.5 ± 3.6 years) were included. After 12 months of ETI therapy, significant improvements were observed in FEV1, CFQ-R, VAS, and endoscopic and radiological CRS scores (all p < 0.05). No patient required sinonasal surgery during follow-up. Staphylococcus aureus colonization was significantly reduced. Atopic patients showed lower radiological improvement than non-atopic subjects. TAS2R38 genotype influenced baseline sinonasal severity, with a trend toward genotype-dependent differences in response to ETI.ConclusionsETI therapy significantly improves CRS severity in pediatric CF patients. Atopy and genetic modifiers may contribute to variability in sinonasal response, supporting a personalized approach to CF-related CRS management.
Background: An increase in hemoglobin (Hb) has been reported in subjects with CF treated with the CFTR modulator Ivacaftor and with the combination Lumacaftor/Ivacaftor (LI), while the literature about the impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Hb levels in the pediatric population is lacking. Materials and Methods: We retrospectively evaluated Hb levels in 35 subjects with CF (18 males, median age: 8 years; interquartile range (IQR): 6–13 years) treated with LI and 60 (24 males, median age: 10 years; IQR: 6–14 years) treated with ETI. For each subject we considered the values of Hb, serum potassium, total bilirubin (TB), and conjugated bilirubin (CB) at baseline, after 3 days, and 1, 3, 6, 9, and 12 months from the start of treatment. Results: In subjects with CF treated with LI, we observed a significant increase in Hb values 3 days after the introduction of the drug, which remained constant throughout the year of treatment. In subjects treated with ETI, a significant decrease in Hb was observed 3 days after the first dose up to 1 month. At 6 months, Hb returned to pre-treatment values remaining stable for up to 12 months. At 3 days of treatment, we also observed a significant increase in serum potassium, which returned to normal at one month, while both TB and CB values significantly increased at 3 days of treatment and remained significantly higher for the whole one-year period of ETI therapy. Conclusions: We confirmed an increase in Hb values over time in subjects treated with LI. While the Hb response in those treated with ETI showed a transient reduction that lasted for one month, this may have depended on hemolysis, and returned to pre-treatment levels. Further studies will clarify the mechanisms that govern changes in Hb in subjects with CF treated with ETI.